A Randomized, Double-Blind, Placebo- and Active Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate Therapy
Latest Information Update: 09 Dec 2022
At a glance
- Drugs Baricitinib (Primary) ; Adalimumab
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms RA-BEAM
- Sponsors Eli Lilly and Company
- 07 Dec 2022 Results from NCT01710358 and NCT01721044 assessing the relative impact of pain and disease activity on improvements in fatigue, published in the JCR: Journal of Clinical Rheumatology
- 22 Feb 2022 Results of an analysis assessing, whether Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and structural damage progression in patients with rheumatoid arthritis using two phase III studies (RA-BEAM and RA-BEGIN) published in the Annals of the Rheumatic Diseases
- 09 Nov 2021 Results assessing effects of Baricitinib on fatigue that are influenced by disease activity and those that are independent of disease activity in patients from the RA-BEAM and RA-BEACON trials, presented at the ACR Convergence 2021